AML classification in the year 2023: How to avoid a Babylonian confusion of languages.

Authors:
Huber S; Baer C; Hutter S; Dicker F; Meggendorfer M and 5 more

Journal:
Leukemia

Publication Year: 2023

DOI:
10.1038/s41375-023-01909-w

PMCID:
PMC10317829

PMID:
37120689

View on PubMed View on PMC View Publisher
Journal Information

Full Title: Leukemia

Abbreviation: Leukemia

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Hematology

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Related Papers from Same Journal
Clonal medicine targeting DNA damage response eradicates leukemia.
Toma MM; Karami A; Nieborowska-Skorska M and 6 more (2024) - Transparency Score: 3/6
Dose modification dynamics of ponatinib in patients with chronic-phase chronic myeloid leukemia (CP…
Jabbour E; Apperley J; Cortes J and 17 more (2024) - Transparency Score: 3/6
LIN28B promotes differentiation of fully transformed AML cells but is dispensable for fetal leukemi…
Li Y; Mendoza-Castrejon J; Patel RM and 4 more (2024) - Transparency Score: 4/6
Lymphoma-associated hemophagocytic lymphohistiocytosis (LA-HLH): a scoping review unveils clinical …
Knauft J; Schenk T; Ernst T and 4 more (2024) - Transparency Score: 3/6
Prognostic impact of CEBPA mutational subgroups in adult AML.
Georgi JA; Stasik S; Kramer M and 35 more (2024) - Transparency Score: 4/6
View All Papers from This Journal
Transparency Score
2/6
33.3% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"Competing interests CH, WK and TH declare part ownership of Munich Leukemia Laboratory (MLL). SH, CB, StH, FD, MM, CP, and GH are employed by the MLL."

Funding Disclosure
Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025